PharmaCyte Biotech, Inc. continues development of its Cell-in-a-Box® technology targeting locally advanced pancreatic cancer (LAPC) amid an ongoing FDA clinical hold. The company reported no revenues but showed a substantial net income in FY2025 driven by non-operating gains. Operating losses narrowed significantly year-over-year, supported by cost controls and strategic investments. Cash and equivalents stood at $20.2 million as of January 31, 2026, with share repurchase programs actively employed to manage capital structure. Nasdaq has issued a compliance warning due to share price below $1, with a deadline in mid-2026 to regain compliance or face delisting risks.